Headache is one of the most common complaints encountered in general clinical practice. Most cases represent primary headache disorders where the pain itself is the central pathology, but a subset stems from dangerous secondary underlying conditions—ranging from infections to severe intracranial vascular events. Distinguishing benign syndromes from life-threatening secondary etiologies relies on systematic clinical evaluation, recognizing diagnostic pitfalls, and applying targeted therapy.
Clinical Concept: Developing the appropriate diagnosis is critical to caring for patients with headache. Patients who have migraine without aura are frequently misdiagnosed as having tension-type headaches and are not offered appropriate therapy.
| Category | Pathophysiology & Definition | Common Clinical Examples |
|---|---|---|
| Primary Headache | Not associated with other underlying diseases. Results from a complex interplay of genetic, developmental, and environmental risk factors. | • Migraine (with or without aura) • Tension-type headache • Cluster headache |
| Secondary Headache | Associated with or directly caused by another condition. Generally does not resolve until the specific underlying cause is addressed. | • Intracranial bleeding or brain tumor • Inflammation, viremia (e.g., influenza), or infection • Increased intracranial pressure (ICP) • Severe hypertension or head/neck trauma |
Reassuring Acute Findings: Reassuring signs that point toward a benign acute clinical encounter include a documented history of previous identical headaches, intact cognitive function, a supple neck, a normal neurological examination, and symptom improvement while under observation.
The SNOOP mnemonic provides a systematic framework to screen for red flag signs that suggest a secondary headache etiology requiring further diagnostic workup:
| Flag | Clinical Features & Warning Signs | Possible Clinical Correlations |
|---|---|---|
| S | Systemic symptoms (fever, unintended weight loss) or secondary risk factors (HIV, malignancy, pregnancy, anticoagulation, blood pressure elevation >180/120 mm Hg). | Meningitis, encephalitis, intracranial inflammation, metastatic disease, intracerebral hemorrhages. |
| N | Newly acquired neurological findings (confusion, impaired alertness, nuchal rigidity, papilledema, cranial nerve dysfunction, motor abnormalities). | CNS infection, mass lesion, stroke, arteriovenous malformation (AVM), collagen vascular disease. |
| O | Sudden, abrupt, or split-second “thunderclap” onset. Onset triggered by exertion, sexual activity, coughing, or sneezing. | Subarachnoid hemorrhage (thunderclap); mass lesion or conditions with increased intracranial pressure. |
| O | New onset in older patients (>50 years) or very young children (<5 years). | Temporal (giant cell) arteritis in older patients; mass lesions. |
| P | Progressive change in quality or frequency; postural change (upright vs. lying down); presence of papilledema or visual problems. | Medication overuse, subdural hematoma, mass lesion, intracranial hypotension, posterior fossa pathology, cervicogenic headache. |
| Disorder | Pain Quality & Location | Duration & Demographics | Associated Features & Diagnostic Criteria |
|---|---|---|---|
| Tension-Type | Pressing, nonpulsatile, band-like quality. Mild-to-moderate intensity; usually bilateral. | 30 minutes to 7 days (typically 1 to 24 hours). Female-to-male ratio is 5:4. | No more than one of the following: mild nausea, photophobia, or phonophobia (not both photophobia and phonophobia). No vomiting. |
| Migraine (without aura) | Pulsating quality, moderate-to-severe intensity, typically unilateral (occasionally bilateral). Aggravated by normal activity like walking. | 4 to 72 hours. Represents ~80% of migraine cases. Female-to-male ratio is 2:1. | Accompanied by nausea/vomiting, photophobia, and phonophobia. Early warning signs may include agitation, jitteriness, or unusual dreams. Positive family history in 70–90%. |
| Migraine (with aura) | Same head pain parameters as migraine without aura. | Represents ~20% of migraine cases. Aura develops over 5 to 20 minutes and lasts <1 hour. | Reversible neurological aura from cerebral cortex or brainstem. Symptoms include visual/olfactory alterations, GI upset, feelings of dread, or nervousness. Headaches are not more severe than those without aura. |
| Cluster Headache | Severe to very severe, strictly unilateral pain centered behind one eye (orbital, supraorbital, or temporal). Described as a “hot poker in the eye” (“suicide headache”). | Lasts 15 to 180 minutes; occurs 1 to 8 times daily in periodic clusters lasting weeks to months. Male predominance (female-to-male ratio 1:3 to 1:8). | Associated with ipsilateral autonomic signs: conjunctival injection, lacrimation, nasal stuffiness, ptosis, miosis, or facial sweating. “Alarm clock” pattern often awakens patients ~1 hour into sleep. ~20% family history. |
Diagnostic Pitfalls: Clinicians frequently misdiagnose migraines because standard International Headache Society (IHS) criteria do not include all clinical manifestations. Migraines accompanied by neck pain are frequently misclassified as tension-type headaches, while those with nasal congestion or rhinorrhea are commonly mislabeled as “sinus” headaches.
Routine neuroimaging yields little additional clinical value and increases costs in patients with nonacute primary headaches who have a normal physical and neurological examination. However, when SNOOP red flags are identified, neuroimaging is indicated:
| Imaging Modality | Clinical Advantages | Limitations & Disadvantages |
|---|---|---|
| CT Scan (Head) | • Rapid scan acquisition (5–10 minutes) • Superior for detecting acute intracranial hemorrhage and bone abnormalities • Lower financial cost • Safe for patients with implantable devices | • Exposes patient to ionizing radiation • Higher risk of allergic reaction to iodinated contrast • Less sensitive for small, subtle soft-tissue lesions |
| MRI (Brain) | • No ionizing radiation exposure • Superior detail for detecting small and subtle parenchymal or tissue lesions • Gadolinium contrast carries a lower risk of allergic reactions | • Longer procedure time (~45 minutes) • Higher overall cost • Cannot be used in patients with certain implantable devices |
In older adults with new-onset headaches, evaluating C-reactive protein (CRP) or erythrocyte sedimentation rate helps rule out giant cell (temporal) arteritis. Additionally, secondary headaches driven by elevated intracranial pressure present uniquely as pain that is worst upon awakening—when brain swelling peaks—and gradually lessens as the patient remains upright throughout the day.
Analgesic Rebound Risk: Regular, long-term use of acute medications can lead to medication-overuse headaches. Over-the-counter combination analgesics (e.g., caffeine/aspirin/acetaminophen formulations like Excedrin Migraine) and prescription drugs containing butalbital (e.g., Fioricet) carry high risks of rebound headaches and dependency. Plain NSAIDs like ibuprofen or naproxen demonstrate a relatively lower risk.
| Drug Class | Representative Agents | Mechanism & Clinical Utility | Safety Warnings & Contraindications |
|---|---|---|---|
| Triptans | Sumatriptan, Rizatriptan, Zolmitriptan, Naratriptan, Frovatriptan | Selective serotonin (5-HT1B/1D) agonists specific for acute migraine relief. Effective for pain, photophobia, and phonophobia. Available in oral, melt tablet, nasal spray, and injectable forms. | Contraindicated in coronary artery disease, Prinzmetal angina, uncontrolled HTN, pregnancy, or recent ergot use due to vasoconstriction. Serotonin syndrome risk with SSRIs/SNRIs. (Frovatriptan is not contraindicated with MAOIs). |
| Ditans | Lasmiditan | Oral selective 5-HT1F receptor agonist. Treats migraine pain, photophobia, phonophobia, and nausea without vasoconstriction. | Schedule V controlled substance. Has significant sedative effects; patients must not drive or operate machinery for at least 8 hours post-dose. |
| Oral Gepants | Rimegepant, Ubrogepant | Small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists. Used for acute migraine with or without aura. | Avoid concomitant use with strong CYP3A4 inhibitors. Dose adjustments required for moderate 3A4 inhibitors. Generally higher cost. |
| NSAIDs & Analgesics | Ibuprofen, Naproxen, Aspirin, Acetaminophen | Inhibits prostaglandin synthesis. Highly effective for tension-type and mild-to-moderate migraine pain. High-dose ibuprofen or naproxen sodium offers fast relief. | Take at first sign of pain. Plain naproxen has a slower onset than naproxen sodium. Can cause GI irritation. |
| Ergot Derivatives | Dihydroergotamine (DHE), Ergotamine tartrate | 5-HT1A and 5-HT1D receptor agonists. Helpful for migraine (including IV administration for severe/intractable status migrainosus). Ineffective for tension-type headaches. | Contraindicated in CAD and pregnancy due to potent vasoconstrictive effects. |
| Antiemetics / Neuroleptics | Prochlorperazine, Promethazine, Metoclopramide, Ondansetron | Used as adjuncts for migraine-associated nausea and pain control. Metoclopramide aids GI prokinesis. Ondansetron (5-HT3 antagonist) is non-sedating. | First-generation neuroleptics carry risks of extrapyramidal movement symptoms (EPS) and sedation. Limit use to 2–3 days per week. |
| Cluster Abortives | 100% High-Flow Oxygen, Subcutaneous/Intranasal Triptans, Lidocaine Spray | Provides rapid abortive therapy for severe, fast-onset cluster headache attacks. | Oral treatments are generally ineffective due to the rapid crescendo and short duration (15–180 mins) of cluster attacks. |
Administration Routes: Oral agents take 30 to 60 minutes for relief and work best for gradual headaches without severe GI distress. Rapidly progressing headaches with severe nausea or vomiting respond better to nasal sprays or subcutaneous/parenteral injectables (which achieve onset in 15 to 30 minutes).
Opioid & Steroid Usage: Systemic corticosteroids (e.g., prednisone 20 mg QID for 2 days) can break severe status migrainosus, intractable migraine, or cluster attacks. Opioids (hydrocodone, oxycodone) should generally be avoided for recurring headaches due to risks of sedation, habituation, dependency, and rebound headaches.
Preventive therapy should be considered when acute treatments are needed frequently or fail to provide adequate relief. The standard clinical goal is a ≥50% reduction in headache frequency, alongside easier-to-treat episodes. Most preventive therapies require 1 to 2 months of continuous use to assess efficacy.
| Class | Recommended First-Line Agents | Clinical Nuances & Key Considerations |
|---|---|---|
| Beta-Blockers | Propranolol, Metoprolol, Atenolol, Nadolol | Propranolol and metoprolol have the strongest clinical evidence for migraine prevention. (Note: Current guidelines do not support using calcium channel blockers like verapamil for primary migraine prevention). |
| Antiepileptic Drugs (AEDs) | Topiramate, Divalproex Sodium, Sodium Valproate | Demonstrated efficacy in reducing migraine frequency. Caution: Most AEDs are teratogenic; counsel patients of reproductive age on effective contraception. Lamotrigine is ineffective for migraine prevention. |
| Antidepressants | Amitriptyline, Nortriptyline (TCAs); Venlafaxine (SNRI) | TCAs are considered first-line for tension-type headache prophylaxis and are effective for migraine prevention. Venlafaxine provides effective SNRI-based prophylaxis. |
| CGRP Inhibitor Monoclonal Antibodies | Erenumab, Fremanezumab, Galcanezumab | Target CGRP neuropeptides or receptors to prevent vasodilation and pain signaling. Subcutaneous injections given monthly or quarterly. Rapid onset (1–2 weeks) with few side effects. Higher financial cost. |
| Cluster Prophylaxis | Calcium Channel Blockers (Verapamil), Lithium, Anticonvulsants | Verapamil and lithium are standard preventive therapies used to shorten or stop cluster cycles. |
| Supplements & Herbals | Petasites (Butterbur), Riboflavin (B2), Magnesium, Feverfew, CoQ10 | Butterbur has the strongest evidence among herbal options. Riboflavin, magnesium, and feverfew offer moderate benefit. Nutritional supplements are unstudied and not advised during pregnancy or lactation. |
Disclaimer: This content is for educational purposes only. Clinical management of headaches requires individual assessment based on medical history, physical examination, and established treatment guidelines.
“`